Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06073418 | Dietary Habits, Nutritional Knowledge and Physical Activity Assessment in Early Stage Breast Cancer Patients(DEMETRA) | recruiting | — | 1,098 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY |
| 1 |
| Sep 21, 2023 |
| clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06035016 | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06000917 | A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer | recruiting | Phase 2 | 62 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981014 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 196 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05976412 | Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer | recruiting | N/A | 1,355 | Ruijin HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT05430399 | Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 349 | Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05928429 | Effects of Cryotherapy on Taxane-Induced Neuropathy in Patients With Breast Cancer | recruiting | N/A | 300 | Maria LendorfOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05916755 | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform(PORTRAIT) | recruiting | — | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05058183 | Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer(Safe-De) | recruiting | N/A | 400 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05904964 | Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) | recruiting | Phase 3 | 288 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04020575 | Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) | recruiting | Phase 1 | 69 | Minerva Biotechnologies CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05795335 | CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer | recruiting | — | 172 | RenJi HospitalOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05851014 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | recruiting | Phase 3 | 350 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05835739 | InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2(IDENTITY) | recruiting | — | 78 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05833659 | Comparison Between Prepectoral and Subpectoral Breast Reconstruction(RESPECT) | recruiting | — | 88 | Beijing Friendship HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04800393 | The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.(TeMP) | recruiting | N/A | 130 | Moscow Clinical Scientific CenterOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05212454 | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks | recruiting | Phase 3 | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05452213 | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients(CAPTOR-BC) | recruiting | Phase 4 | 1,000 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT01763125 | Establishment of a Tumor Bank for Blood Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 4 | Mar 23, 2023 | clinicaltrials |
| NCT01789229 | Establishment of a Tumor Bank for Tissue Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 3 | Mar 23, 2023 | clinicaltrials |
| NCT05638594 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | recruiting | Phase 2 | 236 | Shengjing HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05732051 | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients(NARNIA) | recruiting | Phase 2 | 60 | University Hospital, AkershusOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05766410 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC(ORACLE-RIPA) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04483804 | Application of Radiomics in Breast Cancer | recruiting | — | 2,000 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05762900 | Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients(UNIQUE) | recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05218044 | Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ(DCIS) | recruiting | N/A | 30 | Glendale Adventist Medical Center d/b/a Adventist Health GlendaleOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05753657 | A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. | recruiting | Early Phase 1 | 30 | Rambam Health Care CampusOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03436069 | Identification of New Prognostic Markers for Breast Cancer.(PROBREAST) | recruiting | — | 1,500 | University Hospital, GrenobleOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04690439 | Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema(LymphLight) | recruiting | N/A | 104 | Jessa HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04501523 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC(Apollo) | recruiting | Phase 2 | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05731258 | Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen | recruiting | — | 150 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05462457 | TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes(SenTa2) | recruiting | — | 150 | Kliniken Essen-MitteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05692674 | A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction | recruiting | Phase 2 | 67 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05665920 | Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy(HYPHEN) | recruiting | N/A | 36 | Instituto Brasileiro de Controle do CancerOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04472845 | HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).(HYPART) | recruiting | N/A | 1,018 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03150576 | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer(PARTNER) | recruiting | Phase 2 / Phase 3 | 780 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05502224 | Multidisciplinary Approach to Fatigue | recruiting | N/A | 50 | Jules Bordet InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05603078 | A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)(BIRKIN) | recruiting | N/A | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05587777 | Monitoring of Chronic Conditions in Breast Cancer(REBECCA-1) | recruiting | — | 150 | Helse Stavanger HFOTHER_GOV | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04263298 | Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | recruiting | Phase 3 | 210 | Herui YaoOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT05541367 | Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer | recruiting | — | 80 | Tongji HospitalOTHER | 1 | Sep 15, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2023source: clinicaltrials